Glycosylation of immune system proteins and its role in autoimmune diseases and cancer

Authors

  • Anna Trzyna Department of Biology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland
  • Jacek Tabarkiewicz Department of Immunology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland https://orcid.org/0000-0002-1264-2882
  • Artur Mazur Departament Paediatrics, Paediatric Endocrinology and Diabetes, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland https://orcid.org/0000-0001-5393-3515

DOI:

https://doi.org/10.15584/ejcem.2020.1.7

Keywords:

Glycosylation, Immunity, Cellular, Humoral, Autoimmune Diseases

Abstract

Introduction. Structural glycans have great biological significance and are involved in signaling and cell communication of the immune system. They are attached to proteins and lipids in an enzymatic process called glycosylation where glycosyltransferase and glycosidases bind sugar residues and lead to the formation of bioconjugates.

Aim. In this paper we describe the importance of glycosylation in the immune system and its changes in diseases.

Material and methods. This review was performed according to systematic literature search of major bibliographic databases.

Analysis of the literature. Proper glycosylation ensures the functioning of the organism, however, defects in structural glycans of immune system changes their properties and can lead to disorders and further to autoimmune diseases. It has been also proven that glycosylation of autoimmune system is changed during cancer. In this paper we described types of structural glycans, significance of glycosylation of selected components of the immune system and its modifications in disorders.

Conclusion. Knowledge about changes in the glycosylation in diseases is the key to understanding the processes of autoimmune diseases and may allow the development of new treatments in the future. 

Downloads

Download data is not yet available.

References

Varki A. Biological roles of glycans. Glycobiology. 2017;27(1):3–49.

Lyons JJ, Milner JD, Rosenzweig SD. Glycans Instructing Immunity: The Emerging Role of Altered Glycosylation in Clinical Immunology. Front Pediatr. 2015;3:54.

Clerc F, Reiding KR, Jansen BC, Kammeijer GS, Bondt A, Wuhrer M. Human plasma protein N-glycosylation. Glycoconj J. 2016;33(3):309–343.

Ho WL, Hsu WM, Huang MC, Kadomatsu K, Nakagawara A. Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma. J Hematol Oncol. 2016;9(1):100.

Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 2006 Sep 8;126(5):855-67.

Lairson LL, Henrissat B, Daviesand GJ, Withers SG. Glycosyltransferases: Structures, Functions, and Mechanisms. Annu Rev Biochem. 2008;Vol. 77:521-555.

Stanley P, Taniguchi N, Aebi M. N-Glycans. In: Varki A, Cummings RD, Esko JD, et al., eds. Essentials of Glycobiology. 3rd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2015-2017. Chapter 9. https://www.ncbi.nlm.nih.gov/books/NBK453020/. Access November 18, 2019.

Nagae M, Yamaguchi Y. Function and 3D structure of the N-glycans on glycoproteins. Int J Mol Sci. 2012;13(7):8398–8429.

Roth Z, Yehezkel G, Khalaila I. Identification and Quantification of Protein Glycosylation. Int J Carbohydr Chem. 2012;2012: Article ID 640923.

Mkhikian H, Grigorian A, Li CF, et al. Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat Commun. 2011;2:334.

Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125(2):3–23.

Cabral J, Hanley SA, Gerlach JQ, et al. Distinctive Surface Glycosylation Patterns Associated With Mouse and Human CD4+ Regulatory T Cells and Their Suppressive Function. Front Immunol. 2017;8:987.

Maggi E, Cosmi L, Liotta F, Romagnani P, Romagnani S, Annunziato F. Thymic regulatory T cells. Autoimmun Rev. 2005;4(8):579-586.

Pereira MS, Alves I, Vicente M, et al. Glycans as Key Checkpoints of T Cell Activity and Function. Front Immunol. 2018;9:2754.

Attaf M, Legut M, Cole DK, Sewell AK. The T cell antigen receptor: the Swiss army knife of the immune system. Clin Exp Immunol. 2015;181(1):1–18.

Smith LK, Boukhaled GM, Condotta SA, et al. Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity. Immunity. 2018;48(2):299–312.e5.

Dennis JW, Lau KS, Demetriou M, Nabi IR. Adaptive Regulation at the Cell Surface by N‐Glycosylation. Traffic. 2009;10(11):1569-1578.

Gordon-Alonso M, Hirsch T, Wildmann C, van der Bruggen P. Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. Nat Commun. 2017;8(1):793.

Giovannone N, Antonopoulos A, Liang J, et al. Human B Cell Differentiation Is Characterized by Progressive Remodeling of O-Linked Glycans. Front Immunol. 2018;9:2857.

Xue J, Gao X, Fu C, et al. Regulation of galectin-3-induced apoptosis of Jurkat cells by both O glycans and N-glycans on CD45. FEBS Lett. 2013;587:3986–94.

Zauner G, Selman MH, Bondt A, et al. Glycoproteomic analysis of antibodies. Mol Cell Proteomics. 2013;12(4):856–865.

Plomp R, Bondt A, de Haan N, Rombouts Y, Wuhrer M. Recent Advances in Clinical Glycoproteomics of Immunoglobulins (Igs). Mol Cell Proteomics. 2016;15(7):2217–2228.

Plomp R, Dekkers G, Rombouts Y, et al. Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3). Mol Cell Proteomics. 2015;14(5):1373–1384.

Hoffmann M, Marx K, Reichl U, Wuhrer M, Rapp E. Site-specific O-Glycosylation Analysis of Human Blood Plasma Proteins. Mol Cell Proteomics. 2016;15(2):624–641.

Buettner MJ, Shah SR, Saeui CT, Ariss R, Yarema KJ. Improving Immunotherapy Through Glycodesign. Front Immunol. 2018;9:2485.

Benedetti E, Pučić-Baković M, Keser T, et al. Network inference from glycoproteomics data reveals new reactions in the IgG glycosylation pathway [published correction appears in Nat Commun. 2018;9(1):706]. Nat Commun. 2017;8(1):1483.

Zhao J, Nussinov R, Ma B. Antigen binding allosterically promotes Fc receptor recognition. MAbs. 2019;11(1):58–74.

Shade K.-T.C, Anthony RM. Antibody Glycosylation and Inflammation. Antibodies. 2013;2(3):392-414.

Bondt A, Rombouts Y, Selman MH, et al. Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol Cell Proteomics. 2014;13(11):3029–3039.

Russell A, Adua E, Ugrina I, Laws S, Wang W. Unravelling Immunoglobulin G Fc N-Glycosylation: A Dynamic Marker Potentiating Predictive, Preventive and Personalised Medicine. Int J Mol Sci. 2018;19(2):390.

Nardy AF, Freire-de-Lima L, Freire-de-Lima CG, Morrot A. The Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer Progression. Front Oncol. 2016;6:54.

Ohtsubo K, Takamatsu S, Minowa MT, Yoshida A, Takeuchi M, Marth JD. Dietary and Genetic Control of Glucose Transporter 2 Glycosylation Promotes Insulin Secretion in Suppressing Diabetes. Cell. 2005;123(7):1307-1321.

Rabinovich GA, van Kooyk Y, Cobb BA. Glycobiology of immune responses. Ann N Y Acad Sci. 2012;1253:1–15.

Tabak LA. The role of mucin-type O-glycans in eukaryotic development. Semin Cell Dev Biol. 2010;21(6):616–621.

Ju T, Wang Y, Aryal RP, et al. Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers. Proteomics Clin Appl. 2013;7(9-10):618–631.

Daniels MA, Hogquist KA, Jameson SC. Sweet 'n' sour: the impact of differential glycosylation on T cell responses. Nat Immunol. 2002;3(10):903-10.

Ryan SO, Cobb BA. Roles for major histocompatibility complex glycosylation in immune function. Semin Immunopathol. 2012;34(3):425–441.

Wuhrer M, Selman MH, McDonnell LA, et al. Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. J Neuroinflammation. 2015;12:235.

Jones MB, Oswald DM, Joshi S, Whiteheart SW, Orlando R, Cobb BA. B-cell–independent sialylation of IgG. PNAS. 2016;113(26):7207-7212.

Tanaka T, Yoneyama T, Noro D, et al. Aberrant N-Glycosylation Profile of Serum Immunoglobulins is a Diagnostic Biomarker of Urothelial Carcinomas. Int J Mol Sci. 2017;18(12):2632.

Burchell JM, Beatson R, Graham R, Taylor-Papadimitriou J, Tajadura-Ortega V. O-linked mucin-type glycosylation in breast cancer. Biochem Soc Trans. 2018;46(4):779–788.

Hollander N, Haimovich J. Altered N-Linked Glycosylation in Follicular Lymphoma and Chronic Lymphocytic Leukemia: Involvement in Pathogenesis and Potential Therapeutic Targeting. Front Immunol. 2017;8:912.

Büll C, den Brok MH, Adema GJ. Sweet escape: Sialic acids in tumor immune evasion. Biochim Biophys Acta. 2014;1846(1):238-246.

Winter L, Wong LA, Jerums G, et al. Use of Readily Accessible Inflammatory Markers to Predict Diabetic Kidney Disease. Front Endocrinol (Lausanne). 2018;9:225.

Saeui CT, Nairn AV, Galizzi M, et al. Integration of genetic and metabolic features related to sialic acid metabolism distinguishes human breast cell subtypes. PLoS One. 2018;13(5):e0195812.

Puck A, Hopf S, Modak M, et al. The soluble cytoplasmic tail of CD45 (ct-CD45) in human plasma contributes to keep T cells in a quiescent state. Eur J Immunol. 2017;47(1):193–205.

Munkley J, Elliott DJ. Hallmarks of glycosylation in cancer. Oncotarget. 2016;7(23):35478–35489.

Very N, Lefebvre T, El Yazidi-Belkoura I. Drug resistance related to aberrant glycosylation in colorectal cancer. Oncotarget. 2017;9(1):1380–1402.

Downloads

Published

2020-03-30

How to Cite

Trzyna, A., Tabarkiewicz, J., & Mazur, A. (2020). Glycosylation of immune system proteins and its role in autoimmune diseases and cancer. European Journal of Clinical and Experimental Medicine, 18(1), 32–37. https://doi.org/10.15584/ejcem.2020.1.7

Issue

Vol. 18 No. 1 (2020)

Section

REVIEW PAPERS

License

Copyright (c) 2020 European Journal of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.

Most read articles by the same author(s)